RETAKLIK 2.0 (Retatrutide) 45mg

RETAKLIK 2.0 is a synthetic triple receptor agonist targeting GLP-1, GIP, and glucagon receptor pathways, designed exclusively for in vitro and in vivo laboratory research applications for studying metabolic regulation and receptor signalling in controlled settings. Supplied as 45mg in pre-filled research devices for controlled laboratory and R&D use only. Delivered in sealed format to support formulation assessment, compound stability testing, and delivery system evaluation. All products are for research purposes only. Not for human consumption, medical use, diagnosis, or treatment.

What Is Cagrilintide?

Cagrilintide is the second compound in Retaklik 2.0. It's designed to copy amylin, a hormone the body already makes after eating. Pairing it with Retatrutide — a triple-receptor compound acting on GLP-1, GIP, and glucagon pathways — gives researchers one combination pen to study appetite regulation and metabolic pacing side by side, instead of running two separate products.

What's In The Box

Each order includes one multi-dose pen (40mg Retatrutide + 5mg Cagrilintide in 2.4ml), disposable needles, and an instruction book — everything needed to get started, nothing extra to buy.